Want to see INO full AI Analyst Report?
INO Stock Chart & Stats
$1.19
-$0.22(-9.65%)
At close: 4:00 PM EST
$1.19
-$0.22(-9.65%)
Day’s Range― - ―
52-Week Range$1.03 - $2.98
Previous CloseN/A
Volume1.36M
Average Volume (3M)1.42M
Market Cap
$92.15M
Enterprise Value$91.25
Total Cash (Recent Filing)$37.68M
Total Debt (Recent Filing)$8.70M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 12, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding82,273,240
10 Day Avg. Volume1,186,038
30 Day Avg. Volume1,417,503
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)33.86
Price to Sales (P/S)12485.24
P/FCF Ratio-9.18
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.25Price Target Upside257.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$10.88M
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone (INO‑3107 BLA)BLA acceptance and a defined PDUFA date create a concrete regulatory path to potential approval and U.S. market entry. Mid-cycle review with no new issues materially lowers near-term regulatory uncertainty and supports planning for commercialization and confirmatory trial alignment over the coming months.
Strong Phase I/II EfficacyRobust, durable efficacy signals—large reductions in surgeries and improving outcomes into year two—support a clinically meaningful label and payer conversations. Persistent therapeutic benefit and favorable safety versus comparator strengthen long-term adoption and commercial potential if approved.
Commercial Differentiation & ReadinessOperational advantages—simpler logistics and no surgical requirement—reduce barriers for provider adoption and distribution costs. Established CMO, distributor and specialty-pharmacy relationships signal practical readiness to scale commercial operations quickly after approval, improving time-to-revenue prospects.
Bears Say
Very Weak Financial PerformanceEffectively zero trailing revenue combined with recurring large operating losses indicates the company cannot internally fund development or commercialization. Over months this forces reliance on external capital, increases dilution risk, and constrains strategic choices for product launches and confirmatory trials.
High Cash Burn And Limited RunwaySubstantial quarterly cash burn with runway only into Q1 2027 creates urgent financing needs near key regulatory milestones. This elevates execution risk: potential funding gaps could delay commercialization, shrink launch investments, or force dilutive financings that impair long-term capital structure and partner negotiations.
Balance-sheet DeteriorationRecent shift to leverage where debt exceeds equity signals rising solvency and refinancing risk. Reduced financial flexibility raises borrowing costs, limits ability to support commercial scale-up or large confirmatory programs, and can constrain strategic partnerships due to counterparty credit concerns.
Inovio Pharmaceuticals News
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $1.03 and its highest was $2.98 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $92.15M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 21 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on May 13, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.35 by $0.07.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals pays a Monthly dividend of $0.069 which represents an annual dividend yield of N/A. See more information on Inovio Pharmaceuticals dividends here
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 82,273,240 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.35. Following the earnings report the stock price went up 1.493%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in INO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.25 (257.14% Upside)
$4.25 (257.14% Upside)
Blogger Sentiment
Bullish
INO Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 126.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-42.96%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
INO Stock 12 Month Forecast
Average Price Target
$4.25
▲(257.14% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
14.81% Mutual Funds
0.02% Other Institutional Investors
79.92% Public Companies and
Individual Investors